Actively Recruiting
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-02-24
10
Participants Needed
2
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.
CONDITIONS
Official Title
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and above, male or female
- Diagnosis of antiphospholipid syndrome
- Previous glucocorticoid treatment failed, relapsed, or was not tolerated
- Unable to choose or failed other second-line treatments like rituximab or cyclosporine
- Platelet count less than 30 × 10^9/L
- Liver and kidney function tests within 1.5 times the upper normal limit
- ECOG physical state score of 2 points or less
- New York Heart Association cardiac function classification of 2 or less
- Signed written informed consent
You will not qualify if you...
- Uncontrollable serious diseases such as malignant tumors, liver failure, heart failure, or kidney failure
- HIV positive
- Active uncontrolled infections including hepatitis B, hepatitis C, cytomegalovirus, EB virus, or syphilis
- Severe bleeding such as hemoptysis, upper gastrointestinal bleeding, or intracranial hemorrhage
- Heart diseases, arrhythmias requiring treatment, or poorly controlled hypertension
- Recent thrombotic diseases like new pulmonary embolism or unstable thrombosis
- History of allogeneic stem cell or organ transplantation
- Mental disorders preventing informed consent or trial participation
- Persistent toxic symptoms from previous treatments
- Other serious diseases limiting participation such as diabetes or severe cardiac insufficiency
- Septicemia or other severe irregular bleeding
- Pregnant, suspected pregnancy, or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
2
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
Y
Yunfei Chen, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here